1. Scrip
  2. >>Business
  3. >>Strategy

GW CEO: Cannabinoid Platform Is Growth Engine Beyond Epidiolex

 
• By Sten Stovall

Aside from epilepsy in children, GW Pharma also looking to other therapeutic spaces for testing its cannabinoid product candidates, including autism and brain cancer.

Smiling kid child holding a hemp leaf. Concepts of using marihuna for medicinal purposes for children, Medical use of non-psychoactive cannabidiol CBD
GW Hopes Its cannabidiol-based drugs will treat numerous forms of childhood epilepsy • Source: Shutterstock

With its plant-derived cannabidiol Epidiolex set to be become the first FDA-approved drug for seizures associated with rare childhood epilepsy conditions, GW Pharmaceuticals PLC is also looking to other therapeutic spaces in which to test its cannabinoid product candidates, including autism and brain cancer, the UK-based group's CEO told Scrip.

Further in the future, plant-derived cannabinoid products could offer alternatives to opioids, without the accompanying abuse danger, Justin Gover said in an interview. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.